• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.

作者信息

Horiguchi Miki, Uno Hajime, Wei Lee-Jen

机构信息

Miki Horiguchi, Kitasato University School of Pharmacy, Tokyo, Japan; Hajime Uno, Dana-Farber Cancer Institute, Boston, MA; and Lee-Jen Wei, Department of Biostatistics, Harvard University, Boston, MA.

出版信息

J Clin Oncol. 2018 Mar 1;36(7):720-721. doi: 10.1200/JCO.2017.76.0983. Epub 2018 Jan 16.

DOI:10.1200/JCO.2017.76.0983
PMID:29337638
Abstract
摘要

相似文献

1
Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.因不良事件而停用纳武单抗和伊匹单抗治疗的晚期黑色素瘤患者的生存期明显长于继续治疗的患者。
J Clin Oncol. 2018 Mar 1;36(7):720-721. doi: 10.1200/JCO.2017.76.0983. Epub 2018 Jan 16.
2
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.纳武利尤单抗和伊匹木单抗序贯给药并计划在晚期黑色素瘤患者中进行转换（CheckMate 064）：一项开放标签、随机、2期试验。
Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4.
3
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.纳武单抗联合伊匹单抗或单独使用纳武单抗治疗晚期黑色素瘤相关的神经系统严重不良事件，包括一组脑炎病例
Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.
4
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.纳武利尤单抗治疗后接受伊匹单抗治疗的晚期黑色素瘤患者的回顾性研究：60 例日本患者分析。
J Dermatol Sci. 2018 Jan;89(1):60-66. doi: 10.1016/j.jdermsci.2017.10.009. Epub 2017 Oct 25.
5
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.纳武利尤单抗与伊匹木单抗联合用药对比伊匹木单抗单药治疗晚期黑色素瘤患者：一项多中心、随机、对照、2期试验的2年总生存结果
Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.
6
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.在晚期黑色素瘤患者抗PD-1治疗进展后，使用伊匹单抗单药或与纳武单抗联合治疗。
Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.
7
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.纳武利尤单抗和伊匹单抗联合治疗晚期黑色素瘤患者的汇总分析安全性概况。
J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.
8
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药治疗黑色素瘤脑转移瘤：一项多中心随机 2 期研究。
Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.
9
Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56.纳武利尤单抗对比伊匹单抗用于晚期黑色素瘤的治疗：一项关键性评价：原创文章：Wolchok JD, Chiarion-Sileni V, Gonzalez R 等。纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤的总生存期。《新英格兰医学杂志》2017; 377:1345-56.
Br J Dermatol. 2018 Aug;179(2):296-300. doi: 10.1111/bjd.16785. Epub 2018 Jun 5.
10
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.纳武单抗单药治疗或联合伊匹单抗治疗转移性黑色素瘤：随机对照试验的系统评价和荟萃分析
Melanoma Res. 2018 Oct;28(5):371-379. doi: 10.1097/CMR.0000000000000467.

引用本文的文献

1
Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.III期非小细胞肺癌放化疗后巩固性度伐利尤单抗的最佳疗程：一项多机构回顾性研究
Target Oncol. 2025 Jan;20(1):161-169. doi: 10.1007/s11523-024-01105-5. Epub 2024 Nov 7.
2
Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review.帕博利珠单抗与白蛋白结合型紫杉醇联合治疗转移性肝外胆管癌的持久反应：一例报告及文献综述
Front Pharmacol. 2022 Nov 28;13:1037646. doi: 10.3389/fphar.2022.1037646. eCollection 2022.
3
What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
免疫检查点抑制剂在恶性肿瘤中的最佳持续时间是多久？
Front Immunol. 2022 Sep 26;13:983581. doi: 10.3389/fimmu.2022.983581. eCollection 2022.
4
Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course.免疫检查点抑制剂的给药方案：降低剂量、减少频次、缩短疗程的尝试。
Front Oncol. 2022 Jun 20;12:906251. doi: 10.3389/fonc.2022.906251. eCollection 2022.
5
Safety of sequential immune checkpoint inhibitors after prior immune therapy.序贯免疫检查点抑制剂在既往免疫治疗后的安全性。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2375-2382. doi: 10.1007/s00432-022-04137-4. Epub 2022 Jun 21.
6
Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.接受伊匹单抗和纳武单抗治疗的转移性黑色素瘤患者中，因免疫相关不良事件停药或未停药患者的疗效比较：一项真实世界数据研究
Cancers (Basel). 2021 Nov 5;13(21):5550. doi: 10.3390/cancers13215550.
7
Considerations for treatment duration in responders to immune checkpoint inhibitors.考虑免疫检查点抑制剂应答者的治疗持续时间。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001901.
8
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?临床试验中处理非比例风险的方法：准备好进行初步分析了吗？
J Clin Oncol. 2019 Dec 10;37(35):3455-3459. doi: 10.1200/JCO.19.01681. Epub 2019 Oct 24.
9
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.无治疗生存：免疫检查点抑制作用的新型疗效评估指标——晚期黑色素瘤患者的汇总分析
J Clin Oncol. 2019 Dec 10;37(35):3350-3358. doi: 10.1200/JCO.19.00345. Epub 2019 Sep 9.